CGEN Stock Analysis: Buy, Sell, or Hold?
CGEN - Compugen Ltd
$2.01
-0.02 (-0.74%)
▼
5d:
-1.23%
30d:
-28.39%
90d:
-3.14%
BUY
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 05, 2026
Get Alerted When CGEN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CGEN shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: CGEN shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: CGEN is currently trading at $2.00, which is considered slightly low relative to its 30-day fair value range of $1.98 to $2.63.
Technical Outlook: Technically, CGEN is in a uptrend. The price is currently testing key support at $1.95. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CGEN has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $4.60 (+127.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CGEN is in a uptrend. The price is currently testing key support at $1.95. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CGEN has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $4.60 (+127.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$1.98 -
$2.63
Company Quality Score
51/100
(HOLD)
Options IV Signal
54th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
60.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 54th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 127.7% below Wall St target ($4.60)
Trading Range Analysis
30-Day Trading Range
$1.98 -
$2.63
Current vs Trading Range
SLIGHTLY LOW
Expected Move (7 Days)
±$0.37
(18.3%)
Support & Resistance Levels
Support Level
$1.95
Resistance Level
$2.12
Current Trend
Uptrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.53
Wall Street Target
$4.60
(+127.7%)
Revenue Growth (YoY)
-4.7%
Profit Margin
48.0%
Share & Embed Analysis
Last updated: June 24, 2026 10:02 AM ET
Data refreshes hourly during market hours. Next update: 11:02 AM
Data refreshes hourly during market hours. Next update: 11:02 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CGEN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
Eran Ophir
SELL
5000 shares
2026-04-14
Zurit Levine
SELL
3125 shares
2026-04-10
Zurit Levine
SELL
5375 shares
2026-04-08
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 57 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 64 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$276 | 59 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 65 BUY |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$83 | 61 BUY |
